News - Ipsen

Filter

Current filters:

Ipsen

Popular Filters

1 to 25 of 59 results

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

07-02-2014

French drugmaker Ipsen has announced that the Phase III clinical trial evaluating Decapeptyl (triptorelin…

DecapeptylFranceIpsenOncologyPharmaceuticalResearch

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

Ipsen’s sales grow 2.2% in 2013, but miss expectations

Ipsen’s sales grow 2.2% in 2013, but miss expectations

28-01-2014

French drugmaker Ipsen posted solid sales growth for fourth-quarter and full-year 2013, though there…

FinancialIpsenPharmaceutical

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Ipsen recruits executive VP, technical operations

Ipsen recruits executive VP, technical operations

10-01-2014

French drugmaker Ipsen has appointed Jonathan Barnsley as executive vice president in charge of technical…

BoardroomIpsenManagementPharmaceutical

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

Mixed geographical performance from Ipsen

30-10-2013

French drugmaker Ipsen today reported sales for the third quarter of 2013, noting a significant slowdown…

FinancialIpsenPharmaceutical

PeptiDream and Ipsen expand their peptide drug collaboration to treat endocrinologic disease

07-10-2013

PeptiDream and Ipsen have expanded the scope of their April 2013 research collaboration and license option…

Asia-PacificGastro-intestinalsIpsenLicensingPeptiDreamPharmaceutical

Ipsen hopes study results could lead to additional Somatuline indication

17-09-2013

French drugmaker Ipsen (Euronext: IPN) has released positive clinical trial results for the treatment…

EuropeIpsenNeurologicalPharmaceuticalResearchSomatuline

Ipsen first-half profits rise on flattish sales

30-08-2013

French drugmaker Ipsen (Euronext: IPN) today (August 30) reported first-half 2013 financial results with…

FinancialIpsenPharmaceutical

Ipsen makes acquisition and signs R&D deal with Harvard

15-07-2013

French drugmaker Ipsen (Euronext: IPN) has acquired UK life sciences company Syntaxin for an upfront…

EuropeIpsenMergers & AcquisitionsNeurologicalPharmaceuticalSyntaxin

Trial finds Ipsen's tumor drug Somatuline superior to placebo in delaying disease progression

11-07-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive results from its Phase III study of Somatuline…

EuropeIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen reports mixed Ph III results with Somatuline Autogel in patients with acromegaly

18-06-2013

French drugmaker Ipsen (Euronext: IPN) announced the results of an international Phase IIIb study, PRIMARYS,…

IpsenPharmaceuticalRare diseasesResearchSomatuline

Ipsen expects Increlex supply interruption; 1st-qtr sales up 5.3%

25-04-2013

French drugmaker Ipsen (Euronext: IPN) says that its supplier of Increlex (mecasermin [rDNA origin] Injection)…

FinancialIncrelexIpsenLonzaPharmaceuticalProduction

Ipsen sales up 5% in 2012, though hemophilia exit hits profits; deputy CEO appointed

01-03-2013

French biopharma company Ipsen (Euronext: IPN) posted a 5% increase in drug sales in 2012 to 1.19 billion…

FinancialIpsenManagementPharmaceutical

Launch of Ipsen/Braintree's Eziclen/Izinova in Europe expected by end 2013

07-02-2013

French drugmaker Ipsen (Euronext: IPN) and US partner Braintree Laboratories yesterday announced today…

Braintree LaboratoriesEuropeEziclenGastro-intestinalsIpsenIzinovaPharmaceuticalRegulation

Ipsen and Inspiration Biopharma sell IB1001 rights to Cangene

06-02-2013

French drugmaker Ipsen (Euronext: IPN) and privately-held Inspiration Biopharmaceuticals entered into…

Cangene CorpIB1001Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsPharmaceutical

1 to 25 of 59 results

Back to top